India-based pharmaceutical company Lupin said Wednesday it has launched a drug that is bioequivalent to Supernus Pharmaceuticals' (SUPN) Trokendi XR in the US.

Lupin's Topiramate extended-release capsules were launched after the US Food and Drug Administration approved its Abbreviated New Drug Application, the company said.

The drug is approved for partial-onset seizures, primary generalized tonic-clonic seizures, and Lennox-Gastaut syndrome seizures in patients aged at least 6 years, as well as for prevention of migraines in patients 12 years and older, Lupin said.

Price: 48.94, Change: +0.54, Percent Change: +1.11